Loading…
Reported covered position: Senior Health Policy Advisor, US Senator Barbara Boxer
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Prescription Drug Monitoring Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S. 788; HR 2025.
Prescription Drug Monitoring Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2018 · fourth_quarter · Q4
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices. Researching and responding to the Administration's America's Patients First drug pricing blueprint. Medicare Part B reforms. S 637; HR 1920; HR 1939. Medical utilization management and Medicare Advantage program policy and operations; S 2553 and S 2554 - Prohibition on pharmacy "gag clauses."
Regulatory policies related to the health reform law, including drug benefits and disclosure. Implementation of HITECH. Prescription drug affordability issues, including biosimilars. Reforms to Medicaid and Exchange markets.
Source: Senate LDA
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S. 788; HR 2025; S. 2553 and S. 2554.
Prescription Drug Monitoring Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S. 788; HR 2025; S. 2553 and S. 2554; HR 6.
Prescription Drug Monitoring Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S 788; HR 2025; S 2553 and S 2554; HR 6.
To amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare, and for other purposes.
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap, direct negotiation of prescription drug prices. Researching and responding the Administration's America's Patients First drug pricing blueprint. Medicare Part B reforms. S. 637; HR 1920; HR 1939. Medical utilization management and Medicare Advantage program policy and operations; S. 2553 and S 2554 - Prohibition on pharmacy "gag clauses."
To amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare, and for other purposes.
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices. Researching and responding to the Administration's America's Patients First drug pricing blueprint. Medicare Part B reforms. S 637; HR 1920; HR 1939. Medical utilization management and Medicare Advantage program policy and operations; S 2553 and S 2554 - Prohibition on pharmacy "gag clauses."
To amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare, and for other purposes.
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap, direct negotiation of prescription drug prices. Implementation of opioid abuse "lock in" provisions from CARA. Medicare Part B reforms. S. 637; HR 1920; HR 1939. Medical utilization management and Medicare Advantage program policy and operations.
To amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare, and for other purposes.
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap, direct negotiation of prescription drug prices. Researching and responding the Administration's America's Patients First drug pricing blueprint. Medicare Part B reforms. S. 637; HR 1920; HR 1939. Medical utilization management and Medicare Advantage program policy and operations; S. 2553 and S 2554 - Prohibition on pharmacy "gag clauses."
Ensuring Seniors Access to Local Pharmacies Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices. Researching and responding to the Administration's America's Patients First drug pricing blueprint. Medicare Part B reforms. S 637; HR 1920; HR 1939. Medical utilization management and Medicare Advantage program policy and operations; S 2553 and S 2554 - Prohibition on pharmacy "gag clauses."
Ensuring Seniors Access to Local Pharmacies Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap, direct negotiation of prescription drug prices. Implementation of opioid abuse "lock in" provisions from CARA. Medicare Part B reforms. S. 637; HR 1920; HR 1939. Medical utilization management and Medicare Advantage program policy and operations.
Ensuring Seniors Access to Local Pharmacies Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap, direct negotiation of prescription drug prices. Researching and responding the Administration's America's Patients First drug pricing blueprint. Medicare Part B reforms. S. 637; HR 1920; HR 1939. Medical utilization management and Medicare Advantage program policy and operations; S. 2553 and S 2554 - Prohibition on pharmacy "gag clauses."
Ensuring Seniors Access to Local Pharmacies Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap, direct negotiation of prescription drug prices. Researching and responding the Administration's America's Patients First drug pricing blueprint. Medicare Part B reforms. S. 637; HR 1920; HR 1939. Medical utilization management and Medicare Advantage program policy and operations; S. 2553 and S 2554 - Prohibition on pharmacy "gag clauses."
Abuse-Deterrent Opioids Plan for Tomorrow Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S. 788; HR 2025; S. 2553 and S. 2554.
Abuse-Deterrent Opioids Plan for Tomorrow Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S 788; HR 2025; S 2553 and S 2554; HR 6.
Abuse-Deterrent Opioids Plan for Tomorrow Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S. 788; HR 2025; S. 2553 and S. 2554; HR 6.
Abuse-Deterrent Opioids Plan for Tomorrow Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S. 788; HR 2025.
SUPPORT for Patients and Communities Act
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S 788; HR 2025; S 2553 and S 2554; HR 6.
SUPPORT for Patients and Communities Act
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S. 788; HR 2025; S. 2553 and S. 2554; HR 6.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap, direct negotiation of prescription drug prices. Researching and responding the Administration's America's Patients First drug pricing blueprint. Medicare Part B reforms. S. 637; HR 1920; HR 1939. Medical utilization management and Medicare Advantage program policy and operations; S. 2553 and S 2554 - Prohibition on pharmacy "gag clauses."
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices. Researching and responding to the Administration's America's Patients First drug pricing blueprint. Medicare Part B reforms. S 637; HR 1920; HR 1939. Medical utilization management and Medicare Advantage program policy and operations; S 2553 and S 2554 - Prohibition on pharmacy "gag clauses."
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S. 788; HR 2025; S. 2553 and S. 2554.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S 788; HR 2025; S 2553 and S 2554; HR 6.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S. 788; HR 2025; S. 2553 and S. 2554; HR 6.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap, direct negotiation of prescription drug prices. Researching and responding the Administration's America's Patients First drug pricing blueprint. Medicare Part B reforms. S. 637; HR 1920; HR 1939. Medical utilization management and Medicare Advantage program policy and operations; S. 2553 and S 2554 - Prohibition on pharmacy "gag clauses."
Patient Right to Know Drug Prices Act
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S 788; HR 2025; S 2553 and S 2554; HR 6.
Patient Right to Know Drug Prices Act
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap, direct negotiation of prescription drug prices. Researching and responding the Administration's America's Patients First drug pricing blueprint. Medicare Part B reforms. S. 637; HR 1920; HR 1939. Medical utilization management and Medicare Advantage program policy and operations; S. 2553 and S 2554 - Prohibition on pharmacy "gag clauses."
Patient Right to Know Drug Prices Act
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap, direct negotiation of prescription drug prices. Researching and responding the Administration's America's Patients First drug pricing blueprint. Medicare Part B reforms. S. 637; HR 1920; HR 1939. Medical utilization management and Medicare Advantage program policy and operations; S. 2553 and S 2554 - Prohibition on pharmacy "gag clauses."
Patient Right to Know Drug Prices Act
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices. Researching and responding to the Administration's America's Patients First drug pricing blueprint. Medicare Part B reforms. S 637; HR 1920; HR 1939. Medical utilization management and Medicare Advantage program policy and operations; S 2553 and S 2554 - Prohibition on pharmacy "gag clauses."
Patient Right to Know Drug Prices Act
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S. 788; HR 2025; S. 2553 and S. 2554.
Patient Right to Know Drug Prices Act
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S. 788; HR 2025; S. 2553 and S. 2554; HR 6.
Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap, direct negotiation of prescription drug prices. Implementation of opioid abuse "lock in" provisions from CARA. Medicare Part B reforms. S. 637; HR 1920; HR 1939. Medical utilization management and Medicare Advantage program policy and operations.
Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap, direct negotiation of prescription drug prices. Researching and responding the Administration's America's Patients First drug pricing blueprint. Medicare Part B reforms. S. 637; HR 1920; HR 1939. Medical utilization management and Medicare Advantage program policy and operations; S. 2553 and S 2554 - Prohibition on pharmacy "gag clauses."
Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap, direct negotiation of prescription drug prices. Researching and responding the Administration's America's Patients First drug pricing blueprint. Medicare Part B reforms. S. 637; HR 1920; HR 1939. Medical utilization management and Medicare Advantage program policy and operations; S. 2553 and S 2554 - Prohibition on pharmacy "gag clauses."
Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices. Researching and responding to the Administration's America's Patients First drug pricing blueprint. Medicare Part B reforms. S 637; HR 1920; HR 1939. Medical utilization management and Medicare Advantage program policy and operations; S 2553 and S 2554 - Prohibition on pharmacy "gag clauses."
Veteran Overmedication Prevention Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S 788; HR 2025; S 2553 and S 2554; HR 6.
Veteran Overmedication Prevention Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S. 788; HR 2025; S. 2553 and S. 2554; HR 6.
Veteran Overmedication Prevention Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S. 788; HR 2025.
Veteran Overmedication Prevention Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S. 788; HR 2025; S. 2553 and S. 2554.
Prescription Drug Monitoring Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S. 788; HR 2025.
Prescription Drug Monitoring Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S. 788; HR 2025.
Prescription Drug Monitoring Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, EPCS, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S. 788; HR 2025.
Prescription Drug Monitoring Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S. 788; HR 2025.
To amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare, and for other purposes.
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap, direct negotiation of prescription drug prices. Implementation of opioid abuse "lock in" provisions from CARA. Medicare Part B reforms. S. 637; HR 1920; HR 1939.
To amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare, and for other purposes.
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap, direct negotiation of prescription drug prices. Implementation of opioid abuse "lock in" provisions from CARA. Medicare Part B reforms. S. 637; HR 1920; HR 1939.
To amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare, and for other purposes.
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap, direct negotiation of prescription drug prices. Implementation of opioid abuse "lock in" provisions from CARA. Medicare Part B reforms. S. 637; HR 1920; HR 1939.
To amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare, and for other purposes.
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap, direct negotiation of prescription drug prices. Implementation of opioid abuse "lock in" provisions from CARA. Medicare Part B reforms. S. 637; HR 1920; HR 1939. Medical utilization management and Medicare Advantage program policy and operations.
Ensuring Seniors Access to Local Pharmacies Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap, direct negotiation of prescription drug prices. Implementation of opioid abuse "lock in" provisions from CARA. Medicare Part B reforms. S. 637; HR 1920; HR 1939.
Ensuring Seniors Access to Local Pharmacies Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap, direct negotiation of prescription drug prices. Implementation of opioid abuse "lock in" provisions from CARA. Medicare Part B reforms. S. 637; HR 1920; HR 1939. Medical utilization management and Medicare Advantage program policy and operations.
Ensuring Seniors Access to Local Pharmacies Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap, direct negotiation of prescription drug prices. Implementation of opioid abuse "lock in" provisions from CARA. Medicare Part B reforms. S. 637; HR 1920; HR 1939.
Ensuring Seniors Access to Local Pharmacies Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap, direct negotiation of prescription drug prices. Implementation of opioid abuse "lock in" provisions from CARA. Medicare Part B reforms. S. 637; HR 1920; HR 1939.
Abuse-Deterrent Opioids Plan for Tomorrow Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S. 788; HR 2025.
Abuse-Deterrent Opioids Plan for Tomorrow Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S. 788; HR 2025.
Abuse-Deterrent Opioids Plan for Tomorrow Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S. 788; HR 2025.
Abuse-Deterrent Opioids Plan for Tomorrow Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, EPCS, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S. 788; HR 2025.
Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap, direct negotiation of prescription drug prices. Implementation of opioid abuse "lock in" provisions from CARA. Medicare Part B reforms. S. 637; HR 1920; HR 1939. Medical utilization management and Medicare Advantage program policy and operations.
Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap, direct negotiation of prescription drug prices. Implementation of opioid abuse "lock in" provisions from CARA. Medicare Part B reforms. S. 637; HR 1920; HR 1939.
Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap, direct negotiation of prescription drug prices. Implementation of opioid abuse "lock in" provisions from CARA. Medicare Part B reforms. S. 637; HR 1920; HR 1939.
Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap, direct negotiation of prescription drug prices. Implementation of opioid abuse "lock in" provisions from CARA. Medicare Part B reforms. S. 637; HR 1920; HR 1939.
Veteran Overmedication Prevention Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S. 788; HR 2025.
Veteran Overmedication Prevention Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S. 788; HR 2025.
Veteran Overmedication Prevention Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, EPCS, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S. 788; HR 2025.
Veteran Overmedication Prevention Act of 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S. 788; HR 2025.
Patients' Access to Treatments Act of 2015
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, PBM disclosure, MLR, specialty pharmacy tiering restrictions. Regulatory implementation of a pathway for the approval of biosimilars. REMs. 340b program reform. policies placing restrictions on pharmacy benefit design. Issues regarding making prescription drugs more affordable, including: generic user fees, pedigree, biosimilars, REMs. General issues dealing with prescription drug abuse, including Medicare lock-in programs. General issues dealing with regulating pharmacy drug compounding. HR 1600; S 1190/ HR793.
Patients' Access to Treatments Act of 2015
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, PBM disclosure, MLR, specialty pharmacy tiering restrictions. Regulatory implementation of a pathway for the approval of biosimilars. REMs. 340b program reform. policies placing restrictions on pharmacy benefit design. Issues regarding making prescription drugs more affordable, including: generic user fees, pedigree, biosimilars, REMs. General issues dealing with prescription drug abuse, including Medicare lock-in programs. General issues dealing with regulating pharmacy drug compounding. HR 1600; S 1190/ HR793.
Patients' Access to Treatments Act of 2015
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, PBM disclosure, MLR, specialty pharmacy tiering restrictions. Regulatory implementation of a pathway for the approval of biosimilars. REMs. 340b program reform. policies placing restrictions on pharmacy benefit design. Issues regarding making prescription drugs more affordable, including: generic user fees, pedigree, biosimilars, REMs. General issues dealing with prescription drug abuse, including Medicare lock-in programs. General issues dealing with regulating pharmacy drug compounding. HR 1600; S 1190/ HR793.
Patients' Access to Treatments Act of 2015
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, PBM disclosure, MLR, specialty pharmacy tiering restrictions. Regulatory implementation of a pathway for the approval of biosimilars. REMs. 340b program reform. policies placing restrictions on pharmacy benefit design. Issues regarding making prescription drugs more affordable, including: generic user fees, pedigree, biosimilars, REMs. General issues dealing with prescription drug abuse, including Medicare lock-in programs. General issues dealing with regulating pharmacy drug compounding. HR 1600; S 1190/ HR793.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General Legislative and regulatory issues such as direct negotiation. Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors prompt pay discounts from the definition of average sales prices. Medicare audit and preferred network restrictions. HR 244; HR 793.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General Legislative and regulatory issues such as direct negotiation. Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors prompt pay discounts from the definition of average sales prices. Medicare audit and preferred network restrictions. HR 244; HR 793.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General Legislative and regulatory issues such as direct negotiation. Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors prompt pay discounts from the definition of average sales prices. Medicare audit and preferred network restrictions. HR 244; HR 793.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General Legislative and regulatory issues such as direct negotiation. Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors prompt pay discounts from the definition of average sales prices. Medicare audit and preferred network restrictions. HR 244; HR 793.
National Defense Authorization Act for Fiscal Year 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Pharmacy issues related to the annual defense reauthorization (HR 4909).
National Defense Authorization Act for Fiscal Year 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Pharmacy issues related to the annual defense reauthorization (HR 4909).
National Defense Authorization Act for Fiscal Year 2017
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Pharmacy issues related to the annual defense reauthorization (HR 4909).
Ensuring Seniors Access to Local Pharmacies Act of 2015
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, PBM disclosure, MLR, specialty pharmacy tiering restrictions. Regulatory implementation of a pathway for the approval of biosimilars. REMs. 340b program reform. policies placing restrictions on pharmacy benefit design. Issues regarding making prescription drugs more affordable, including: generic user fees, pedigree, biosimilars, REMs. General issues dealing with prescription drug abuse, including Medicare lock-in programs. General issues dealing with regulating pharmacy drug compounding. HR 1600; S 1190/ HR793.
Ensuring Seniors Access to Local Pharmacies Act of 2015
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, PBM disclosure, MLR, specialty pharmacy tiering restrictions. Regulatory implementation of a pathway for the approval of biosimilars. REMs. 340b program reform. policies placing restrictions on pharmacy benefit design. Issues regarding making prescription drugs more affordable, including: generic user fees, pedigree, biosimilars, REMs. General issues dealing with prescription drug abuse, including Medicare lock-in programs. General issues dealing with regulating pharmacy drug compounding. HR 1600; S 1190/ HR793.
Ensuring Seniors Access to Local Pharmacies Act of 2015
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, PBM disclosure, MLR, specialty pharmacy tiering restrictions. Regulatory implementation of a pathway for the approval of biosimilars. REMs. 340b program reform. policies placing restrictions on pharmacy benefit design. Issues regarding making prescription drugs more affordable, including: generic user fees, pedigree, biosimilars, REMs. General issues dealing with prescription drug abuse, including Medicare lock-in programs. General issues dealing with regulating pharmacy drug compounding. HR 1600; S 1190/ HR793.
Ensuring Seniors Access to Local Pharmacies Act of 2015
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General Legislative and regulatory issues such as direct negotiation. Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors prompt pay discounts from the definition of average sales prices. Medicare audit and preferred network restrictions. HR 244; HR 793.
Ensuring Seniors Access to Local Pharmacies Act of 2015
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, PBM disclosure, MLR, specialty pharmacy tiering restrictions. Regulatory implementation of a pathway for the approval of biosimilars. REMs. 340b program reform. policies placing restrictions on pharmacy benefit design. Issues regarding making prescription drugs more affordable, including: generic user fees, pedigree, biosimilars, REMs. General issues dealing with prescription drug abuse, including Medicare lock-in programs. General issues dealing with regulating pharmacy drug compounding. HR 1600; S 1190/ HR793.
Ensuring Seniors Access to Local Pharmacies Act of 2015
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General Legislative and regulatory issues such as direct negotiation. Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors prompt pay discounts from the definition of average sales prices. Medicare audit and preferred network restrictions. HR 244; HR 793.
Ensuring Seniors Access to Local Pharmacies Act of 2015
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General Legislative and regulatory issues such as direct negotiation. Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors prompt pay discounts from the definition of average sales prices. Medicare audit and preferred network restrictions. HR 244; HR 793.
Ensuring Seniors Access to Local Pharmacies Act of 2015
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General Legislative and regulatory issues such as direct negotiation. Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors prompt pay discounts from the definition of average sales prices. Medicare audit and preferred network restrictions. HR 244; HR 793.
To repeal the annual fee on health insurance providers enacted by the Patient Protection and Affordable Care Act.
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Regulatory implementation of various tax provisions in the health reform law, including the health insurer tax (HR 928/ S 183).
To repeal the annual fee on health insurance providers enacted by the Patient Protection and Affordable Care Act.
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Regulatory implementation of various tax provisions in the health reform law, including the health insurer tax (HR 928/ S 183).
To repeal the annual fee on health insurance providers enacted by the Patient Protection and Affordable Care Act.
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Regulatory implementation of various tax provisions in the health reform law, including the health insurer tax (HR 928/ S 183).
To repeal the annual fee on health insurance providers enacted by the Patient Protection and Affordable Care Act.
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Regulatory implementation of various tax provisions in the health reform law, including the health insurer tax (HR 928/ S 183).
Ensuring Seniors Access to Local Pharmacies Act of 2015
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, PBM disclosure, MLR, specialty pharmacy tiering restrictions. Regulatory implementation of a pathway for the approval of biosimilars. REMs. 340b program reform. policies placing restrictions on pharmacy benefit design. Issues regarding making prescription drugs more affordable, including: generic user fees, pedigree, biosimilars, REMs. General issues dealing with prescription drug abuse, including Medicare lock-in programs. General issues dealing with regulating pharmacy drug compounding. HR 1600; S 1190/ HR793.
Ensuring Seniors Access to Local Pharmacies Act of 2015
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, PBM disclosure, MLR, specialty pharmacy tiering restrictions. Regulatory implementation of a pathway for the approval of biosimilars. REMs. 340b program reform. policies placing restrictions on pharmacy benefit design. Issues regarding making prescription drugs more affordable, including: generic user fees, pedigree, biosimilars, REMs. General issues dealing with prescription drug abuse, including Medicare lock-in programs. General issues dealing with regulating pharmacy drug compounding. HR 1600; S 1190/ HR793.
Ensuring Seniors Access to Local Pharmacies Act of 2015
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, PBM disclosure, MLR, specialty pharmacy tiering restrictions. Regulatory implementation of a pathway for the approval of biosimilars. REMs. 340b program reform. policies placing restrictions on pharmacy benefit design. Issues regarding making prescription drugs more affordable, including: generic user fees, pedigree, biosimilars, REMs. General issues dealing with prescription drug abuse, including Medicare lock-in programs. General issues dealing with regulating pharmacy drug compounding. HR 1600; S 1190/ HR793.
Ensuring Seniors Access to Local Pharmacies Act of 2015
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, PBM disclosure, MLR, specialty pharmacy tiering restrictions. Regulatory implementation of a pathway for the approval of biosimilars. REMs. 340b program reform. policies placing restrictions on pharmacy benefit design. Issues regarding making prescription drugs more affordable, including: generic user fees, pedigree, biosimilars, REMs. General issues dealing with prescription drug abuse, including Medicare lock-in programs. General issues dealing with regulating pharmacy drug compounding. HR 1600; S 1190/ HR793.
Regulatory implementation of various tax provisions in the health reform law, including the health insurer tax (HR 928/ S 183).
Regulatory implementation of various tax provisions in the health reform law, including the health insurer tax (HR 928/ S 183).
Regulatory implementation of various tax provisions in the health reform law, including the health insurer tax (HR 928/ S 183).
Regulatory implementation of various tax provisions in the health reform law, including the health insurer tax (HR 928/ S 183).
Patients' Access to Treatments Act of 2015
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, PBM disclosure, MLR, specialty pharmacy tiering restrictions. Regulatory implementation of a pathway for the approval of biosimilars. REMs. 340b program reform. policies placing restrictions on pharmacy benefit design. Issues regarding making prescription drugs more affordable, including: generic user fees, pedigree, biosimilars, REMs. General issues dealing with prescription drug abuse, including Medicare lock-in programs. General issues dealing with regulating pharmacy drug compounding. HR 1600.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General Legislative and regulatory issues such as direct negotiation. Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors prompt pay discounts from the definition of average sales prices. Medicare audit and preferred network restrictions. HR 244; HR 793.
Ensuring Seniors Access to Local Pharmacies Act of 2015
Client: EXPRESS SCRIPTS, INC. · Firm: EXPRESS SCRIPTS, INC.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General Legislative and regulatory issues such as direct negotiation. Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors prompt pay discounts from the definition of average sales prices. Medicare audit and preferred network restrictions. HR 244; HR 793.
Implementation of tax provisions of the ACA and tax reform policies.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S 788; HR 2025; S 2553 and S 2554; HR 6.
Pharmacy issues related to the annual defense authorization and implementation of the 2018 NDAA.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), Office of Personnel Management (OPM), SENATE, White House Office
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2018 · third_quarter · Q3
Regulatory policies related to the health reform law, including drug benefits and disclosure. Implementation of HITECH. Prescription drug affordability issues, including biosimilars. Reforms to Medicaid and Exchange markets.
Pharmacy issues related to the annual defense authorization and implementation of the 2018 NDAA.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap, direct negotiation of prescription drug prices. Researching and responding the Administration's America's Patients First drug pricing blueprint. Medicare Part B reforms. S. 637; HR 1920; HR 1939. Medical utilization management and Medicare Advantage program policy and operations; S. 2553 and S 2554 - Prohibition on pharmacy "gag clauses."
Implementation of tax provisions of the ACA and tax reform policies.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S. 788; HR 2025; S. 2553 and S. 2554; HR 6.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), Office of Personnel Management (OPM), SENATE, White House Office
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2018 · second_quarter · Q2
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S. 788; HR 2025; S. 2553 and S. 2554.
Pharmacy issues related to the annual defense authorization and implementation of the 2018 NDAA.
Implementation of tax provisions of the ACA and tax reform policies.
Regulatory policies related to the health reform law, including drug benefits and disclosure. Implementation of HITECH. Prescription drug affordability issues, including biosimilars. Reforms to Medicaid and Exchange markets.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap, direct negotiation of prescription drug prices. Researching and responding the Administration's America's Patients First drug pricing blueprint. Medicare Part B reforms. S. 637; HR 1920; HR 1939. Medical utilization management and Medicare Advantage program policy and operations; S. 2553 and S 2554 - Prohibition on pharmacy "gag clauses."
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), Office of Personnel Management (OPM), SENATE, White House Office
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2018 · first_quarter · Q1
Pharmacy issues related to the annual defense authorization and implementation of the 2017 NDAA.
Regulatory policies related to the health reform law, including drug benefits and disclosure. Implementation of HITECH. Prescription drug affordability issues. Reforms to Medicaid and Exchange markets.
Implementation of tax provisions of the ACA, including the insurer tax. Tax reform policies.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S. 788; HR 2025.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap, direct negotiation of prescription drug prices. Implementation of opioid abuse "lock in" provisions from CARA. Medicare Part B reforms. S. 637; HR 1920; HR 1939. Medical utilization management and Medicare Advantage program policy and operations.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), Office of Personnel Management (OPM), SENATE, White House Office
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2017 · fourth_quarter · Q4
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap, direct negotiation of prescription drug prices. Implementation of opioid abuse "lock in" provisions from CARA. Medicare Part B reforms. S. 637; HR 1920; HR 1939. Medical utilization management and Medicare Advantage program policy and operations.
Implementation of tax provisions of the ACA, including the insurer tax. Tax reform policies.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S. 788; HR 2025.
Pharmacy issues related to the annual defense authorization and implementation of the 2017 NDAA.
Regulatory policies related to the health reform law, including drug benefits and disclosure. Implementation of HITECH. Prescription drug affordability issues. Reforms to Medicaid and Exchange markets.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), Office of Personnel Management (OPM), SENATE, White House Office
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2017 · third_quarter · Q3
Implementation of tax provisions of the ACA, including the insurer tax. Tax reform policies.
Pharmacy issues related to the annual defense authorization and implementation of the 2017 NDAA.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S. 788; HR 2025.
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2017 · second_quarter · Q2
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap, direct negotiation of prescription drug prices. Implementation of opioid abuse "lock in" provisions from CARA. Medicare Part B reforms. S. 637; HR 1920; HR 1939.
Pharmacy issues related to the annual defense authorization and implementation of the 2017 NDAA.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, EPCS, electronic prior authorization, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S. 788; HR 2025.
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2017 · first_quarter · Q1
Pharmacy issues related to the annual defense authorization and implementation of the 2017 NDAA.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap, direct negotiation of prescription drug prices. Implementation of opioid abuse "lock in" provisions from CARA. Medicare Part B reforms. S. 637; HR 1920; HR 1939.
Design and coverage of pharmacy benefits in Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, EPCS, PBM disclosure, MLR, and specialty pharmacy tiering. Implementation of biosimilars pathway from BPCIA. Policies placing restrictions on pharmacy benefit design. Issues relating to prescription drug affordability. REMS reform. Prescription drug user fee reauthorization. HR 1854; S. 788; HR 2025.
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2016 · fourth_quarter · Q4
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General Legislative and regulatory issues such as direct negotiation. Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors prompt pay discounts from the definition of average sales prices. Medicare audit and preferred network restrictions. HR 244; HR 793.
Regulatory policies related to the health reform law: structure, drug benefits, disclosure. Regulatory implementation of HITECH/accounting of disclosures. Issues regarding making prescription drugs more affordable. Restrictions on specialty tiering.
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2016 · third_quarter · Q3
Regulatory policies related to the health reform law: structure, drug benefits, disclosure. Regulatory implementation of HITECH/accounting of disclosures. Issues regarding making prescription drugs more affordable. Restrictions on specialty tiering.
Regulatory implementation of various tax provisions in the health reform law, including the health insurer tax (HR 928/ S 183).
Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, PBM disclosure, MLR, specialty pharmacy tiering restrictions. Regulatory implementation of a pathway for the approval of biosimilars. REMs. 340b program reform. policies placing restrictions on pharmacy benefit design. Issues regarding making prescription drugs more affordable, including: generic user fees, pedigree, biosimilars, REMs. General issues dealing with prescription drug abuse, including Medicare lock-in programs. General issues dealing with regulating pharmacy drug compounding. HR 1600; S 1190/ HR793.
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2016 · second_quarter · Q2
Regulatory policies related to the health reform law: structure, drug benefits, disclosure. Regulatory implementation of HITECH/accounting of disclosures. Issues regarding making prescription drugs more affordable. Restrictions on specialty tiering.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General Legislative and regulatory issues such as direct negotiation. Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors prompt pay discounts from the definition of average sales prices. Medicare audit and preferred network restrictions. HR 244; HR 793.
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2016 · first_quarter · Q1
Postal reform proposals, including rate reform, and their impact on 6 day mail delivery.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General Legislative and regulatory issues such as direct negotiation. Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors prompt pay discounts from the definition of average sales prices. Medicare audit and preferred network restrictions. HR 244; HR 793.
Regulatory policies related to the health reform law: structure, drug benefits, disclosure. Regulatory implementation of HITECH/accounting of disclosures. Issues regarding making prescription drugs more affordable. Restrictions on specialty tiering.
EXPRESS SCRIPTS, INC. via EXPRESS SCRIPTS, INC.
2015 · fourth_quarter · Q4
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General Legislative and regulatory issues such as direct negotiation. Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors prompt pay discounts from the definition of average sales prices. Medicare audit and preferred network restrictions. HR 244; HR 793.
Regulatory policies related to the health reform law: structure, drug benefits, disclosure. Regulatory implementation of HITECH/accounting of disclosures. Issues regarding making prescription drugs more affordable. Restrictions on specialty tiering.
Regulatory policies related to the health reform law, including drug benefits and disclosure. Implementation of HITECH. Prescription drug affordability issues. Reforms to Medicaid and Exchange markets.
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap, direct negotiation of prescription drug prices. Implementation of opioid abuse "lock in" provisions from CARA. Medicare Part B reforms. S. 637; HR 1920; HR 1939.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), Office of Personnel Management (OPM), SENATE, White House Office
Regulatory policies related to the health reform law, including drug benefits and disclosure. Implementation of HITECH. Prescription drug affordability issues. Reforms to Medicaid and Exchange markets.
Implementation of tax provisions of the ACA, including the insurer tax. Tax reform policies.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), Office of Personnel Management (OPM), SENATE, White House Office
Implementation of tax provisions of the ACA, including the insurer tax. Tax reform policies.
Regulatory policies related to the health reform law, including drug benefits and disclosure. Implementation of HITECH. Prescription drug affordability issues. Reforms to Medicaid and Exchange markets.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), Office of Personnel Management (OPM), SENATE, White House Office
Pharmacy issues related to the annual defense reauthorization (HR 4909).
Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, PBM disclosure, MLR, specialty pharmacy tiering restrictions. Regulatory implementation of a pathway for the approval of biosimilars. REMs. 340b program reform. policies placing restrictions on pharmacy benefit design. Issues regarding making prescription drugs more affordable, including: generic user fees, pedigree, biosimilars, REMs. General issues dealing with prescription drug abuse, including Medicare lock-in programs. General issues dealing with regulating pharmacy drug compounding. HR 1600; S 1190/ HR793.
Postal reform proposals, including rate reform, and their impact on 6 day mail delivery.
Regulatory implementation of various tax provisions in the health reform law, including the health insurer tax (HR 928/ S 183).
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), Office of Personnel Management (OPM), SENATE, White House Office
Pharmacy issues related to the annual defense reauthorization (HR 4909).
Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General Legislative and regulatory issues such as direct negotiation. Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors prompt pay discounts from the definition of average sales prices. Medicare audit and preferred network restrictions. HR 244; HR 793.
Postal reform proposals, including rate reform, and their impact on 6 day mail delivery.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), Office of Personnel Management (OPM), SENATE, White House Office
Regulatory implementation of various tax provisions in the health reform law, including the health insurer tax (HR 928/ S 183).
Postal reform proposals, including rate reform, and their impact on 6 day mail delivery.
Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, PBM disclosure, MLR, specialty pharmacy tiering restrictions. Regulatory implementation of a pathway for the approval of biosimilars. REMs. 340b program reform. policies placing restrictions on pharmacy benefit design. Issues regarding making prescription drugs more affordable, including: generic user fees, pedigree, biosimilars, REMs. General issues dealing with prescription drug abuse, including Medicare lock-in programs. General issues dealing with regulating pharmacy drug compounding. HR 1600; S 1190/ HR793.
Pharmacy issues related to the annual defense reauthorization (HR 4909).
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), Office of Personnel Management (OPM), SENATE, White House Office
Regulatory implementation of various tax provisions in the health reform law, including the health insurer tax (HR 928/ S 183).
Pharmacy issues related to the annual defense reauthorization.
Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, PBM disclosure, MLR, specialty pharmacy tiering restrictions. Regulatory implementation of a pathway for the approval of biosimilars. REMs. 340b program reform. policies placing restrictions on pharmacy benefit design. Issues regarding making prescription drugs more affordable, including: generic user fees, pedigree, biosimilars, REMs. General issues dealing with prescription drug abuse, including Medicare lock-in programs. General issues dealing with regulating pharmacy drug compounding. HR 1600; S 1190/ HR793.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), Office of Personnel Management (OPM), SENATE, White House Office
Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, PBM disclosure, MLR, specialty pharmacy tiering restrictions. Regulatory implementation of a pathway for the approval of biosimilars. REMs. 340b program reform. policies placing restrictions on pharmacy benefit design. Issues regarding making prescription drugs more affordable, including: generic user fees, pedigree, biosimilars, REMs. General issues dealing with prescription drug abuse, including Medicare lock-in programs. General issues dealing with regulating pharmacy drug compounding. HR 1600.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), Office of Personnel Management (OPM), SENATE, White House Office